Results for Bimagrumab in Obesity and Type 2 Diabetes presented by MorphoSys`s Partner
(WorldNews Germany)

November 11, 2019 / 10:02 pm, CET Planegg/Munich, Germany, November 11, 2019 Results for Bimagrumab in Obesity and Type 2 Diabetes presented by MorphoSys`s Partner MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) announced today that its licensee Novartis presented phase 2 results for bimagrumab, a human anti-activin receptor monoclonal antibody developed by Novartis and generated utilizing MorphoSys`s proprietary HuCAL antibody technology. The data from the trial in overweight and obese adults with type 2 diabetes (T2D) were presented on November 7 as a late breaking poster at the Obesity Week 2019 in Las Vegas, USA. According to the abstract, the double-blinded,...